On August 27, 2019, Zhuhai Ruisplei Biopharmaceutical Co., Ltd. (referred to as 'Respley' or the 'Company') held a round of financing signing and launching ceremony for entering the healthy harbor at Zhuhai International Health Port. This signing The ceremony was highly valued by the leaders of relevant government departments. The leaders who attended this event included Huang Jianming, deputy director of the Provincial Small and Medium-sized Enterprise Bureau, Ye Hongyan, deputy director of the Zhuhai Bureau of Industry and Information Technology, and Li Taoyan, deputy director of the People’s Government of Jinwan District, Zhuhai , Xie Kairan, Director of Guangdong Small and Micro Enterprise Entrepreneurship Innovation Base Alliance.
This round of financing was led by Waige Capital, and was jointly funded by investment institutions such as Zhuhai Gree Venture Capital Co., Ltd., Shenzhen Yanghe Biomedical Industry Investment Co., Ltd., and Zhuhai Kangdelai Medical Equipment Co., Ltd.
Li Taoyan, Deputy District Governor of Jinwan District, said in her speech: “The biomedical industry in Jinwan District will gather to build a biomedical production area with an output value of 100 billion in the next 10 years. Four of the top 100 pharmaceutical companies in Zhuhai have entered the list, among which Jinwan District Only 3 seats are occupied, highlighting that Jinwan District has a good foundation for the biomedical industry chain. At the same time, the Jinwan District government has also issued a series of talent policies to attract outstanding domestic and foreign talents to start their own businesses in Jinwan District.'
In his speech, the chairman of Resproly said that 'Before the establishment of the company, I visited all over the country and was finally attracted by Zhuhai's good biomedical industry development ecological environment, supporting facilities, and the future investment and financing environment of the Guangdong-Hong Kong-Macao Greater Bay Area. I was also moved by the Jinwan District Government’s strong sense of service and high administrative efficiency, and was moved by the enthusiasm of the leaders of the Jinwan District. In the end, it was determined that this is our treasured land for development, and we decided to settle in the Jinwan District of Zhuhai.'
There are 30 million asthma patients and 80 million chronic obstructive patients in China, and there is a potential market of 60 billion yuan. The prospects are huge. However, due to the high technical threshold, the patents for heavy explosives have expired, but there are still no generic drugs in China. Respley is a R&D-driven company that takes high-end imitations of blockbuster drugs in the respiratory system field as its entry point; uses years of mainstream product research and development experience, Know-how, etc. as technology-driven, and at the same time, the company is bold in innovation and will Combination of imitation and innovation, and independent innovation of drugs to expand the product line.
Wang Kai, managing partner of Waige Capital, said: “At present, there is a huge unmet clinical demand for respiratory diseases represented by asthma and COPD in China. However, inhaled preparations are the main treatment methods for asthma and COPD. Drugs, due to their complex technology and extremely high R&D thresholds, the country is currently basically at the stage of import monopoly. We believe that this situation will be broken by excellent pharmaceutical companies like Respril in the future.'
signing ceremony
